A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
Phase 1 – testing safety in a small group of people
Conditions:
Advanced relapsed or refractory ovarian cancer
Advanced relapsed or refractory endometrial cancer
Advanced relapsed or refractory germ cell tumours
Sponsor: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 65 participants
БГ